Pharmaceutical Executive-05-01-2014

Pharmaceutical Executive

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

Pharmaceutical Executive

MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.

Pharmaceutical Executive

We check back with previous Pharm Exec Brand of the Year winners to see how things are going.

Pharmaceutical Executive

Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.

Pharmaceutical Executive
From the Editor

May 01, 2014

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

Features

May 01, 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.

Pharmaceutical Executive

Digital technology has changed the risk relationship between brands, HCPs, and patients – it's vital to get that technology working right the first time.